Effect of a conjugate of polymyxin B-dextran 70 in horses with experimentally induced endotoxemia

American Journal of Veterinary Research

Volumn 60, Issue 1, 1999, Pages 68-75

  MacKay, Robert J ^a   Clark, Carol K ^a,c   Logdberg, Lennart ^b,d   Lake, Philip ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c Peterson and Smith Equine   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CYTOKINE; KETOPROFEN; LIPOPOLYSACCHARIDE; POLYMYXIN B; POLYMYXIN DERIVATIVE; PROSTAGLANDIN SYNTHASE INHIBITOR; THROMBOXANE B2; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY TEMPERATURE; BREATHING RATE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ENDOTOXEMIA; EXPERIMENTAL INFECTION; FEMALE; HEART RATE; HORSE; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE COUNT; NEPHROTOXICITY; NONHUMAN;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTICOAGULANTS; BODY TEMPERATURE; CROSS-OVER STUDIES; CYCLOOXYGENASE INHIBITORS; DEXTRANS; DRUG COMBINATIONS; ENDOTOXEMIA; FEMALE; HEART RATE; HEMATOCRIT; HORSE DISEASES; HORSES; INFUSIONS, INTRAVENOUS; INTERLEUKIN-6; KETOPROFEN; LEUKOCYTE COUNT; LIPID A; LIPOPOLYSACCHARIDES; MALE; POLYMYXIN B; RANDOM ALLOCATION; THROMBOXANE B2; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA; EQUIDAE; EQUUS CABALLUS;

EID: 0032897999     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Morris DD. Equine endotoxemia: a review of cellular and humoral mediators involved in its pathogenesis. J Vet Intern Med 1991;5:167-181.
2. Talan DA. Recent developments in our understanding of sepsis: evaluation of anti-endotoxin antibodies and biological response modifiers. Ann Emerg Med 1993;22:1871-1890.
3. MacKay RJ, Merritt AM, Zertuche J-M, et al. Tumor necrosis factor activity in the circulation of horses given endotoxin. Am J Vet Res 1991;52:533-538.
4. Henry MM, Moore JN, Fischer JK. Influence of an omega-3 fatty acid-enriched ration on in vivo responses of horses to endotoxin. Am J Vet Res 1991;52:523-527.
5. Clark ES, Gantley B, Moore JN. Effects of slow infusion of a low dosage of endotoxin on systemic haemodynamics in conscious horses. Equine Vet J 1991;23:18-21.
6. MacKay RJ, King RR, Dankert JR, et al. Cytotoxic tumor necrosis factor activity produced by equine alveolar macrophages: preliminary characterization. Vet Immunol lmmunopathol 1991;29:15-30.
7. Greisman SE, DuBuy JB, Woodward CL. Experimental gram-negative bacterial sepsis: prevention of mortality not preventable by antibiotics alone. Infect Immun 1979;25:538-557.
8. Baumgartner JD, Heumann D, Gerain J, et al. Association between protective efficacy of anti-lipopolysaccharide (LPS) antibodies and suppression of LPS-induced tumor necrosis factor alpha and interleukin 6. Comparison of O side chain-specific antibodies with core LPS antibodies. J Exp Med 1990;171:889-896.
9. Zanetti G, Glauser MP, Baumgartner JD. Anti-endotoxin antibodies and other inhibitors of endotoxin. New Horiz 1993;1:110-119.
10. Spier SJ, Lavoie J-P, Cullor JS, et al. Protection against clinical endotoxemia in horses by using plasma containing antibody to an Rc mutant E. coli (J5). Circ Shock 1989;28:235-248.
11. Ziegler EJ, McCutchan JA, Fierer J, et al. Treatment of gram-negative bacteremia and shock wilh human antiserum to a mutant Escherichia coli. N Engl J Med 1982;307:1225-1230.
12. McCloskey RV, Straube RC, Sanders C. et al Treatment of septic shock with human monoclonal antibody HA-IA. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group. Ann Intern Med 1994;121:1-5.
13. Fink MP. Adoptive immunotherapy of gram-negative sepsis: use of monoclonal antibodies to lipopolysaccharide. Crit Care Med 1993;21:S32-S39.
14. Morrison DC, Jacobs DM. Binding of polymyxin B to the lipid A portion of bacterial lipopolysaccharides. Immunochemistry 1976;13:813-818.
15. Durando MM, MacKay RJ, Linda S, et al. Effects of polymyxin B and Salmonella typhimurium antiserum on horses given endotoxin intravenously. Am J Vet Res 1994;55:921-927.
16. Endo S, Inada K, Kikuchi M, et al. Clinical effects of intramuscular administration of a small dose of polymyxin B to patients with endotoxemia. Res Commun Chem Pathol Pharmacol 1994;83:223-235.
17. Hughes B, Madan BR, Parratt JR. Polymyxin B sulphate protects cats against the haemodynamic and metabolic effects of E. coli endotoxin. Br J Pharmacol 1981;74:701-707.
18. From AH, Fong JS, Good RA. Polymyxin B sulfate modification of bacterial endotoxin: effects on the development of endotoxin shock in dogs. Infect Immun 1979;23:660-664.
19. Rifkind D. Prevention by polymyxin B of endotoxin lethality in mice. J Bacteriol 1967;93:1463-1464.
20. Fekety FR, Jr, Norman P, Cluff LE. The treatment of gram-negative bacillary infections with colistin. Ann Intern Med 1962;57:214-229.
21. Price DJE, Graham DI. Effects of large doses of colistin sulphomethonate sodium on renal function. Br Med J 1970;4: 525-527.
22. Thelestam M, Mollby R. Cultured human fibroblasts as a model for evaluation of potential in vivo toxicity of membrane damaging antibiotics. Chem Biol Interact 1980;29:315-325.
23. HsuChen CC, Feingold DS. The mechanism of polymyxin B action and selectivity toward biologic membranes. Biochemistry 1973;12:2105-2111.
24. Handley DA, Lake P. Polymyxin B conjugates. US patent 5 177 059. January-5, 1993.
25. Coyne CP, Moritz JT, Fenwick BW. Inhibition of lipopolysaccharide-induced TNF-alpha production by semisynthetic polymyxin-B conjugated dextran. Biotechnol Ther 1994;5:137-162.
26. Bucklin SE, Lake P, Logdberg L, et al. Therapeutic efficacy of a polymyxin B-dextran 70 conjugate in experimental model of endotoxemia. Antimicrob Agent Chemother 1995;39:1462-1466.
27. MacKay RJ, Lester GD. Induction of the acute-phase cytokine, hepatocyte-stimulating factor/interleukin 6, in the circulation of horses treated with endotoxin. Am J Vet Res 1992;53:1285-1289.
28. Landoni MF, Lees P. Pharmacokinetics and pharmacodynamics of ketoprofen enantiomers in the horse. J Vet Pharmacol Ther 1996;19:466-474.
29. Munster AM, Winchurch RA, Thupari JN, et al. Reversal of postburn immunosuppression with low-dose polymyxin B. J Trauma 1986;26:995-998.
30. Endo S, Inada K, lnoue Y, et al. Treatment of endotoxemia with low-dose intramuscular injections or oral administration of polymyxin B. Clin Therapeut 1992;14:64-67.
31. Darrow DH, Keithley EM. Reduction of endotoxin-induced inflammation of the middle ear by polymyxin B. Laryngoscope 1996;106:1028-1033.
32. Baldwin G, Alpert G, Caputo GL, et al. Effect of polymyxin B on experimental shock from meningococcal and Escherichia coli endotoxins. J Infect Dis 1991;164:542-549.
33. van Miert AS, van Duin CT, Wensing T. Effects of pentoxifylline and polymyxin B on the acute-phase-response to Escherichia coli endotoxin in dwarf goats. J Vet Pharmacol Ther 1997;20:61-68.
34. Rifkind D, Hill RB. Neutralization of the Schwartzman reactions by polymyxin B. J Immunol 1967;99:564-569.
35. Rifkind D, Palmer JD. Neutralization of endotoxin toxicity in chick embryos by antibiotics. J Bacteriol 1966;92:815-819.
36. Corrigan JJ Jr, Bell BM. Endotoxin-induced intravascular coagulation: prevention with polymyxin B sulfate. J Lab Clin Med 1971;77:802-810.
37. Komiya S, Tachibana M. Target sites of polymyxin B ototoxicity. Eur Arch Otorhinolaryngol 1990;247:129-130.
38. Scale TW, Rennert OM. Mechanisms of antibiotic-induced nephrotoxicity. Ann Clin Lab Sci 1992;12:1-9.
39. Berg JR, Spilker CM, Lewis SA. Effects of polymyxin B on mammalian urinary bladder. J Membr Biol 1996;154:119-130.
40. Voitenko VG, Bayramashvili DI, Zebrev AI, et al. Relationship between structure and histamine releasing action of polymyxin B and its analogues. Agents Actions 1990;30:153-156.
41. Ralsbeck MF, Garner HE, Osweiler GD. Effects of polymyx in B on selected features of equine carbohydrate overload. Vet Hum Toxicol 1989;31:422-426.
42. Smith WL, Meade EA, DeWitt DL. Pharmacology of prostaglandin endoperoxide synthase isozymes-1 and -2. Ann NY Acad Sci 1994;714:136-142.
43. Uhlig S, Nusing R. von Bethmann A, et al. Cyclooxygenase-2-dependent bronchoconstriction in perfused rat lungs exposed to endotoxin. Mol Med 1996;2:373-383.
44. Tempel GE, Martin HF III. The beneficial effects of a thromboxane receptor antagonist on spinal cord perfusion following experimental cord injury. J Neurol Sci 1992;109:162-167.
45. Suzuki MM, Mikami T, Matumoto T, et al. Gelation of Limulus lysate by synthetic dextran derivatives. Microbiol Immunol 1977;21:419-425.
46. Tanaka T, Iimori M, Tsukatani H, et al. Platelet-aggregating effects of platelet-activating factor-like phospholipids formed by oxidation of phosphatidylcholines containing an sn-2-polyunsaturated fatty acyl group. Biochim Biophys Acta 1994;1210:202-208.
47. Rainger GE, Fisher AC, Nash GB. Endothelial-borne platelet-activating factor and interleukin-8 rapidly immobilize rolling neutrophils. Am J Physiol 1997;272:H114-H122.
48. Ziv G, Nouws JF, van Ginneken CA. The pharmacokinetics and tissue levels of polymyxin B, colistin and gentamicin in calves. J Vet Pharmacol Ther 1982;5:45-58.